Formoterol

Introduction Overview

Generic Name

formoterol

Brand Name

Foradil Aerolizer, Perforomist

Dosage Form

Inhalation powder (capsule), Inhalation solution (nebulizer)

Drug Class

Adrenergic bronchodilators

Pharmacokinetics

Absorption:
Formoterol is rapidly absorbed via the pulmonary route when administered by inhalation. Following inhalation, therapeutic effects begin typically within 1-3 minutes, with peak bronchodilator effect occurring at approximately 30-60 minutes. The systemic bioavailability via inhalation is limited but contributes to systemic side effects. Post-inhalation, formoterol demonstrates rapid onset due to its high lipid solubility enabling rapid penetration of bronchial smooth muscle cells. Absorption from the gastrointestinal tract after oral ingestion of swallowed drug (from inhaler or capsules) is also rapid but subject to first-pass metabolism which reduces bioavailability.

Distribution:
Formoterol shows extensive distribution into body tissues, particularly pulmonary tissue, aligning with its site of action. It is moderately bound to plasma proteins (~61-64%), primarily albumin. The drug exhibits a volume of distribution indicative of significant extravascular penetration. The high affinity to beta-2 adrenergic receptors in bronchial smooth muscle facilitates effective bronchodilation. Distribution is influenced by lipid solubility allowing rapid onset of action.

Metabolism:
Metabolism of formoterol primarily occurs in the liver via direct conjugation and O-demethylation mediated by cytochrome P450 enzymes (notably CYP2D6 and CYP2C19). This biotransformation leads to formation of inactive metabolites, which significantly reduces systemic active drug concentrations. Polymorphisms in metabolizing enzymes may modulate drug levels and response, but overall clinical impact is limited. Metabolic inactivation minimizes prolonged systemic beta-2 adrenergic effects.

Elimination:
Elimination occurs mainly through renal excretion of metabolites and unchanged drug to a lesser extent. The terminal elimination half-life ranges approximately 10 hours following inhalation, supporting twice-daily dosing. Formoterol’s urinary excretion ensures clearance, and renal impairment may alter elimination kinetics though dose adjustment is not clearly required. Biliary excretion is minimal. The steady state is usually achieved within several doses with predictable pharmacokinetics, supporting its use in maintenance therapy.

Dosage Forms

Available Dosage Forms:
- Inhalation powder capsules (Foradil Aerolizer): 12 micrograms per capsule, capsule intended for oral inhalation using a dry powder inhaler.
- Inhalation solution (Perforomist) for nebulization: 20 micrograms per vial (1 ml/vial), administered via jet nebulizer.

Dosages for Adults and Adolescents:
- Asthma prophylaxis and maintenance therapy:
- Inhalation powder: 12 mcg (1 capsule) by oral inhalation every 12 hours for patients 5 years and older.
- Inhalation solution (nebulizer): 20 mcg (1 vial) twice daily for adults; not recommended in children.
- Exercise-induced bronchospasm:
- Inhalation powder: 12 mcg (1 capsule) used at least 15 minutes before exercise.
- Maintenance treatment of COPD:
- Inhalation powder: 12 mcg every 12 hours.
- Inhalation solution: 20 mcg twice daily (do not exceed 40 mcg per day).

Specific Patient Populations:
- Pediatric: Safety and efficacy established for inhalation powder in patients aged 5 years and older. Not recommended in children younger than 5 years or for inhalation solution use in pediatrics.
- Geriatric: No specific dose adjustment; caution advised due to increased likelihood of cardiovascular disease.
- Patients with lactose intolerance or milk protein allergy should use inhalation powder formulation cautiously as capsules contain lactose and milk proteins.
- Renal or hepatic impairment: Specific dose adjustments not clearly delineated but clinical monitoring recommended.
- Storage considerations: Powder capsules should remain in blister packs until use and stored at room temperature. Nebulizer solution stored refrigerated, can be kept at room temperature up to 3 months post-opening; discard if unused after that time.

Mechanism Of Action

Formoterol is a selective long-acting beta-2 adrenergic receptor agonist (LABA) that exerts its pharmacologic effect through stimulation of beta-2 receptors predominantly found on bronchial smooth muscle cells. Upon binding, it activates adenylate cyclase via Gs protein coupling, resulting in increased intracellular cyclic AMP (cAMP) levels. Elevated cAMP leads to activation of protein kinase A which reduces intracellular calcium concentrations, causing relaxation of bronchial smooth muscle and subsequent bronchodilation.

Unlike short-acting beta-2 agonists, formoterol has a prolonged duration of action, up to 12 hours, due to its high lipophilicity allowing it to partition into lipid bilayers and slowly release at the receptor site. This lipophilicity also contributes to its rapid onset of action within minutes, advantageous for quick relief of bronchoconstriction when used regularly.

Besides direct smooth muscle relaxation, formoterol inhibits the release of mediators from mast cells and inhibits microvascular leakage contributing to its anti-inflammatory properties indirectly. It does not possess intrinsic anti-inflammatory efficacy but enhances the efficacy of inhaled corticosteroids when used concomitantly.

Clinically, formoterol is employed for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) to prevent bronchospasm. The combination with corticosteroids is standard to reduce the risk of severe exacerbations. Formoterol’s efficacy and safety profile are supported by clinical trials demonstrating reduction in frequency and severity of bronchospasm episodes. Compared to other LABAs like salmeterol, formoterol provides a faster onset of bronchodilation, which may improve patient symptom control. Research continues into its receptor binding kinetics and potential benefits in combination therapies.

Pharmacological Actions

Selective beta-2 adrenergic receptor agonist activity causing bronchodilation.
Rapid onset of action (within minutes) coupled with prolonged duration (~12 hours).
Relaxes bronchial smooth muscle, leading to airway dilation and improved airflow.
Inhibits release of bronchoconstrictive mediators from mast cells.
Reduces airway hyperresponsiveness to bronchospastic stimuli.
Facilitates mucus clearance by relaxing airway smooth muscle.
Enhances effectiveness of inhaled corticosteroids in asthma management.
Improves symptoms and lung function in chronic obstructive pulmonary disease (COPD).
Prevents exercise-induced bronchospasm when administered prior to exercise.
Minimal affinity for beta-1 adrenergic receptors, limiting cardiac side effects compared to non-selective beta agonists.
Does not relieve acute bronchospasm attacks; intended for maintenance therapy.
Exhibits lipophilic properties responsible for sustained receptor activation.
Demonstrates dose-dependent bronchodilatory and protective effects.
Improves patient quality of life by reducing frequency of asthma and COPD exacerbations.

Therapeutic Or Clinical Uses

Maintenance treatment of asthma in patients 5 years and older in combination with inhaled corticosteroids.
Prevention and control of bronchospasm in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Prophylaxis of exercise-induced bronchospasm (EIB) in patients susceptible to bronchospasm triggered by exercise.
Part of combination therapy regimens for patients not adequately controlled on corticosteroids alone.
Long-term maintenance therapy for airflow obstruction in obstructive pulmonary diseases.
Used to improve lung function and reduce frequency and severity of asthma attacks.
Adjunct therapy in severe asthma requiring dual bronchodilator and anti-inflammatory treatment.
Not intended for relief of acute bronchospasm or status asthmaticus.
Off-label use in select cases may include prevention of bronchospasm in other reversible airway diseases.
Provides improved symptom control and decreased nocturnal symptoms in asthma and COPD.
Helps reduce reliance on short-acting beta-2 agonists for symptom management.
Used in patients with coexisting asthma and COPD requiring beta-2 agonist bronchodilation.
May be used as part of step-up therapy in asthma management guidelines.

Side Or Adverse Effects

Common respiratory symptoms including cough, throat irritation, hoarseness, and dry throat.
Headache and dizziness, which may be dose-related.
Tremor or shakiness, predominantly of hands and limbs.
Palpitations, tachycardia, or irregular heartbeats owing to systemic beta-2 stimulation.
Muscle cramps and increased muscular pain in some patients.
Nervousness, restlessness, and insomnia possibly due to systemic adrenergic effects.
Hypokalemia, manifested by muscle weakness or cramps, especially with higher doses or prolonged use.
Paradoxical bronchospasm causing wheezing or breathing difficulty requiring immediate cessation of drug.
Allergic reactions including rash, itching, swelling (angioedema), and anaphylaxis in rare cases.
Chest pain or tightness potentially related to cardiac stimulation or underlying heart disease.
Increased blood glucose levels which may impact diabetic patients requiring monitoring.
Nausea, vomiting, and gastrointestinal discomfort reported infrequently.
Rare occurrences of seizures or convulsions with overdose or sensitive individuals.
Dry mouth and nasal congestion as minor adverse effects.
Potential worsening of asthma symptoms if used without concomitant corticosteroids.

Precautions

Not to be used for relief of acute bronchospasm or severe asthma or COPD attacks.
Use with caution in patients with underlying cardiovascular conditions including arrhythmias and ischemic heart disease.
Monitor serum potassium levels, especially in patients on diuretics or at risk for hypokalemia.
Use caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders.
Avoid use in patients with known hypersensitivity to formoterol or lactose (capsule excipient).
Should only be used as add-on therapy in asthma patients inadequately controlled on corticosteroids.
Elderly patients may have increased susceptibility to adverse cardiovascular effects.
Evaluate for potential drug interactions before initiating therapy.
Patients should be instructed on proper inhalation technique to maximize efficacy and minimize adverse effects.
Do not abruptly discontinue inhaled corticosteroids when starting formoterol; continue regular corticosteroid therapy unless directed by a physician.
Regular medical follow-up is essential to assess therapeutic response and adverse effects.
Ensure patients understand the difference between maintenance therapy and rescue medication use.
Avoid concomitant use with other LABA-containing medications to prevent overdose.
Caution in patients with lactose intolerance due to capsule constituents.
Advise patients to seek immediate medical attention if experiencing chest pain, severe tremors, or paradoxical bronchospasm.

Warnings

Increased risk of severe asthma exacerbations or asthma-related death if used as monotherapy without inhaled corticosteroids.
Potential for paradoxical bronchospasm which may be life-threatening; discontinue immediately if this occurs.
May cause serious allergic reactions including anaphylaxis and angioedema.
Use is contraindicated during acute asthma attacks or severe COPD exacerbations.
Formoterol can cause significant cardiovascular effects including hypertension, arrhythmias, and myocardial ischemia.
Use with caution in patients with prolonged QT interval or on medications that prolong QT interval.
Risk of hypokalemia may be enhanced by concomitant use of other medications like diuretics or corticosteroids.
Not approved for use in children under 5 years of age (inhalation powder) and in pediatric population for nebulized form.
Medication should not be stopped abruptly without physician guidance, especially corticosteroids.
Avoid concomitant use with other LABA drugs to mitigate risk of overdose and side effects.
Careful monitoring is necessary for patients with diabetes as formoterol may elevate blood glucose levels.
Risk of worsening asthma control or new-onset wheezing may occur without proper concomitant anti-inflammatory therapy.
Avoid in patients with hypersensitivity to drug components including milk proteins in the capsules.
If patients require increased use of short-acting inhalers, this indicates worsening disease and requires medical evaluation.
Immediate medical attention is required for symptoms of overdose including muscle spasms, irregular heartbeat, or severe chest pain.

Contraindication

Hypersensitivity to formoterol or any component of the formulation including lactose and milk proteins in capsules.
Use during acute asthma attacks or severe worsening of COPD symptoms.
Concomitant use with other long-acting beta-2 adrenergic agonists due to risk of additive toxicity.
Known history of QT prolongation or significant cardiac arrhythmias without careful monitoring.
Patients receiving monoamine oxidase inhibitors or within 14 days of stopping such treatment.
Patients with pheochromocytoma due to risk of hypertensive crisis from sympathomimetic agents.
Use in children under 5 years of age for inhalation powder and not recommended for inhalation solution in pediatric patients.
Patients with hypersensitivity reactions to similar beta-2 agonists (cross-reactivity possible).
Severe lactose intolerance when using inhalation powder capsules.
Concurrent use with medications contraindicated for sympathomimetic agents (e.g., certain antiarrhythmics as listed).

Drug Interactions

Contraindicated with bepridil, cisapride, dronedarone, levoketoconazole, mesoridazine, pimozide, piperaquine, saquinavir, sparfloxacin, terfenadine, thioridazine, and ziprasidone due to risk of QT prolongation and serious arrhythmias.
Use caution with beta-blockers (e.g., atenolol, propranolol, metoprolol) as they may reduce bronchodilatory effect and precipitate bronchospasm.
Increased risk of hypokalemia with concomitant use of diuretics, corticosteroids, amphotericin B, or xanthines.
Cautious use with other sympathomimetics or adrenergic agonists to avoid additive cardiovascular effects.
CYP enzyme inhibitors like ketoconazole, itraconazole, and clarithromycin may increase systemic levels of formoterol or related beta-2 agonists.
Interaction with tricyclic antidepressants or monoamine oxidase inhibitors may potentiate cardiovascular effects.
Co-administration with digoxin may require monitoring for arrhythmias due to electrolyte disturbances.
Concurrent use with other LABAs such as salmeterol or arformoterol is not recommended.
Caution with medications that prolong QT interval, including certain antipsychotics, antibiotics, and antiarrhythmics.
Interactions with antidiabetic drugs may require monitoring of blood glucose levels due to potential elevations caused by formoterol.
Alcohol and tobacco use may impact the effectiveness or increase side effects; discuss usage with healthcare provider.
Concomitant use with corticosteroids does not generally cause interactions but combined therapy is required for safety in asthma.
Reports of reduced bronchodilator effects with non-selective beta-blockers necessitate careful management.
Interact with drugs like erythromycin and azithromycin that can affect metabolism and cardiac conduction.
Multiple pharmacodynamic and pharmacokinetic interactions highlight the need for medical supervision and patient education.

Preparations Of The Drug

Foradil Aerolizer: Capsules containing 12 micrograms of formoterol fumarate dihydrate for inhalation powder, supplied in blister cards to be used with the Aerolizer dry powder inhaler device.
Perforomist: Unit-dose vials containing 20 micrograms of formoterol fumarate inhalation solution (1 mL per vial) for nebulization using a jet nebulizer connected to an air compressor.
Packaging designed to protect medication integrity, e.g., foil pouches for capsules to maintain dryness and potency.
Patient leaflets and medication guides included to instruct proper inhaler/nebulizer use.
Both formulations are prescription-only medications due to need for medical supervision for dosing and monitoring.
Storage recommendations: capsules stored at room temperature away from moisture and light; solution stored refrigerated with allowance for short-term room temperature storage.
Devices associated with administration include the Foradil Aerolizer dry powder inhaler and jet nebulizers suitable for Perforomist solution.
Each preparation accompanied by clear dosing instructions emphasizing twice daily administration and avoiding use for acute symptomatic relief.
Preparation design considers patient ease-of-use to maximize adherence and therapeutic effectiveness in chronic airway diseases.
Formulations are free from propellants; inhalation powder uses dry powder technology while solution is preservative-free for nebulization.